Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 6/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | ACACA | Q13085 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2394933 | 0.83 | DRD2 (0.41) | FAAHACHEMAPTALDH1A1JAK1 | |
| SCHEMBL2378339 | 0.81 | DRD2 (0.42) | FAAHACHEMAPTALDH1A1DRD2 | |
| SCHEMBL2378345 | 0.81 | DRD2 (0.42) | FAAHACHEMAPTALDH1A1DRD2 | |
| SCHEMBL2369122 | 0.81 | FAAH (0.48) | FAAHACHEMAPTALDH1A1PKM | |
| SCHEMBL2380298 | 0.80 | ALDH1A1 (0.41) | FAAHACHEMAPTALDH1A1DRD2 | |
| SCHEMBL2380608 | 0.80 | ALDH1A1 (0.41) | FAAHACHEMAPTALDH1A1DRD2 | |
| SCHEMBL2388891 | 0.80 | FAAH (0.42) | FAAHACHEMAPTALDH1A1AR | |
| SCHEMBL2473267 | 0.80 | FAAH (0.53) | FAAHACHEMAPTALDH1A1AR | |
| SCHEMBL2379332 | 0.78 | FAAH (0.40) | FAAHACHEMAPTALDH1A1PKM | |
| SCHEMBL2391387 | 0.78 | GPR119 (0.39) | FAAHACHEMAPTALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539345-B1 | 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INT (DE) | 2015-07-22 | — | — | EP | disclosed |
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217311-A1 | CYCLOALKYL CONTAINING THIENOPYRIMIDINES FOR PHARMACEUTICAL COMPOSITIONS | DTYMK, CMPK1, UCK2 | FAAH 4705/4885ACHE 4289/4885ACACB 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.